- Home
- SRG vs PLYX Comparison
SRG vs PLYX Comparison
Compare SRG & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRG | PLYX |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.5M | 112.7M |
| IPO Year | 2014 | 2025 |
Fundamental Metrics
Financial Performance| Metric | SRG | PLYX |
|---|---|---|
| Price | $1.56 | $1.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | ★ 140.5K | 20.1K |
| Earning Date | 11-20-2026 | 11-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 53.90 | ★ 77.53 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,204,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3.30 | N/A |
| 52 Week Low | $1.55 | $1.69 |
| 52 Week High | $4.23 | $10.93 |
Technical Indicators
Market Signals| Indicator | SRG | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 40.46 | 50.93 |
| Support Level | $1.57 | $1.87 |
| Resistance Level | $1.71 | $2.18 |
| Average True Range (ATR) | 0.08 | 0.11 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 9.43 | 73.35 |
Price Performance
Historical ComparisonAbout SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, sale, and leasing of diversified retail and mixed-use properties throughout the United States.
About PLYX Polaryx Therapeutics Inc. Common Stock
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.